Lexaria Bioscience (NASDAQ:LEXX,CSE:LXX) concluded its expanded research program for DehydraTECH-enabled remdesivir and ebastine, showing effective results in inhibiting the COVID-19 SARS-CoV-2 virus. Lexaria Bioscience CEO Chris Bunka discussed the technology’s potential to treat viral infections via oral delivery and help save billions in the drug administration process.

“Our delivery from oral to the bloodstream is at least two minutes. We’re outrageously fast for oral technology. We’ve been able to improve the delivery rates by 35 percent and 45 percent previously reported on December 1, 2020,” said Bunka.

The study shows DehydraTECH™ improves delivery into the bloodstream of orally administered remdesivir and ebastine. The result may be relevant with additional antiviral drugs within their classes for indications including and beyond COVID-19.

lexaria biosciences logo

This CEO Interview is brought to you by:

Lexaria Bioscience Corp.  (NASDAQ:LEXX, CSE:LXX) is a technology company with a robust patent portfolio for the improved delivery of bioactive compounds. The company is leveraging its proprietary technology for better-tasting, faster-acting and more potent cannabis edibles.Send me an Investor Kit

“We are looking at repurposing some of these drugs, being able to take an antiviral drug that traditionally could only be administered, for example, by injection. We might be able to apply it in an oral form through a pill.”

According to Bunka, delivering an antiviral drug that was originally designed for an injectable form through a new oral form could help governments or health insurance companies save billions of dollars just in administration costs.

Watch the full interview with Lexaria Bioscience CEO Chris Bunka above. 


This interview is sponsored by Lexaria Bioscience (NASDAQ:LEXX, CSE:LXX). This interview provides information which was sourced by the Investing News Network (INN) and approved by Lexaria Bioscience Corp. in order to help investors learn more about the company. Lexaria Bioscience is a client of INN. The company’s campaign fees pay for INN to create and update this interview.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Lexaria Bioscience and seek advice from a qualified investment advisor.

Harvest Health & Recreation Inc. (“Harvest”) ( CSE: HARV OTCQX: HRVSF ), a vertically integrated cannabis company and multi-state operator in the U.S., today announced the opening of a new medical dispensary in Kissimmee, Florida .

Keep reading... Show less

Adastra Holdings Ltd. (formerly Phyto Extractions Inc.) (CSE: XTRX) (FRA: D2EP) (” Adastra ” or the ” Company “) is pleased to announce that it has entered into a share purchase agreement dated September 15, 2021 (the ” Share Purchase Agreement “) pursuant to which the Company has agreed to acquire all the issued and outstanding shares of 1204581 B.C. Ltd., doing business as Phyto Extractions (” Phyto Extractions “) from the shareholders (each, a ” Vendor “) of Phyto Extractions (the ” Acquisition “).

Keep reading... Show less
  • Four SKUs of Pura Earth branded dermacosmetics have been successfully registered with ARCSA, imported into Ecuador, and will be distributed and commercialized through previously announced partnership with Spenta S.A.
  • This marks the 12 th country and market opening of Avicanna’s product offerings.

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

Avicanna Inc. (” Avicanna ” or the ” Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has completed product registration and its first commercial export of its Pura Earth branded dermacosmetics products in Ecuador.

Keep reading... Show less

The Canadian Securities Exchange (“CSE” or “the Exchange”) today announced its market statistics for the month of August 2021, which was highlighted by large financings in the cannabis and mining sectors.

August 2021 Operating Statistics

Keep reading... Show less

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Company”) today announced the voting results from its annual general and special meeting of shareholders held on September 14, 2021 (the “Meeting”).

Keep reading... Show less